Published in Kidney Int on February 01, 2005
Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest (2011) 5.75
Mediators of inflammation in acute kidney injury. Mediators Inflamm (2010) 2.05
Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest (2006) 1.57
Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol (2006) 1.47
Complement Factor B Production in Renal Tubular Cells and Its Role in Sodium Transporter Expression During Polymicrobial Sepsis. Crit Care Med (2016) 1.39
Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol (2015) 1.24
Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci (2006) 1.09
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int (2011) 1.00
Pathogenesis of acute kidney injury: foundation for clinical practice. Am J Kidney Dis (2011) 0.98
IRF-1 promotes inflammation early after ischemic acute kidney injury. J Am Soc Nephrol (2009) 0.96
Role of surfactant proteins A and D in sepsis-induced acute kidney injury. Shock (2015) 0.91
Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4. FASEB J (2014) 0.87
Allograft rejection: effect of local synthesis of complement. Springer Semin Immunopathol (2005) 0.85
The role of the complement system in acute kidney injury. Semin Nephrol (2013) 0.83
Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol (2012) 0.83
Role of complement in multiorgan failure. Clin Dev Immunol (2012) 0.83
Enhancing complement control on endothelial barrier reduces renal post-ischemia dysfunction. J Surg Res (2011) 0.81
Complement regulation in renal disease models. Semin Nephrol (2013) 0.80
Obstacles in haemocompatibility testing. Scientifica (Cairo) (2013) 0.79
Update of acute kidney injury: intensive care nephrology. Hippokratia (2011) 0.78
Loss of CD11b exacerbates murine complement-mediated tubulointerstitial nephritis. PLoS One (2014) 0.77
Moving beyond supportive care--current status of specific therapies in pediatric acute kidney injury. Pediatr Nephrol (2013) 0.77
Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World J Transplant (2014) 0.76
Acute kidney injury: quoi de neuf? Ochsner J (2014) 0.76
ANDSystem: an Associative Network Discovery System for automated literature mining in the field of biology. BMC Syst Biol (2015) 0.75
Role of Keratinocyte Growth Factor in the Differentiation of Sweat Gland-Like Cells From Human Umbilical Cord-Derived Mesenchymal Stem Cells. Stem Cells Transl Med (2015) 0.75
Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol (2016) 0.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature (2009) 4.83
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest (2006) 3.51
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet (2009) 3.36
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum (2011) 2.74
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
The central role of the alternative complement pathway in human disease. J Immunol (2006) 2.53
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol (2008) 2.38
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One (2012) 2.18
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med (2006) 2.16
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem (2005) 2.05
Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol (2006) 2.01
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol (2007) 1.97
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res (2005) 1.94
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther (2007) 1.88
The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum (2010) 1.86
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood (2011) 1.82
CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol (2006) 1.81
Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol (2008) 1.79
Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology (2010) 1.75
Chemoprevention of prostate cancer. J Urol (2009) 1.70
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol (2003) 1.68
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol (2005) 1.67
Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol (2010) 1.65
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am (2010) 1.60
Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol (2007) 1.59
A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum (2009) 1.59
Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol (2002) 1.58
Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int (2004) 1.57
Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest (2006) 1.57
The MAPP research network: design, patient characterization and operations. BMC Urol (2014) 1.56
Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res (2003) 1.55
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol (2005) 1.54
Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum (2012) 1.52
B7-H4 overexpression in ovarian tumors. Gynecol Oncol (2005) 1.51
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol (2008) 1.49
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol (2014) 1.47
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem (2009) 1.45
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol (2007) 1.45
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40
Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol (2007) 1.39
Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol (2006) 1.38
Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol (2009) 1.38
Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.36
Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol (2009) 1.32
Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol (2006) 1.32
Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int (2005) 1.32
The structure of human CD23 and its interactions with IgE and CD21. J Exp Med (2005) 1.28
Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum (2006) 1.28
Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol (2005) 1.26
Innate autoimmunity. Adv Immunol (2005) 1.26
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 1.25
Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation (2007) 1.24
Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol (2004) 1.20
Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol (2008) 1.19
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate (2012) 1.18
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol (2008) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol (2013) 1.17
Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int (2005) 1.17
The role of the immune response in age-related macular degeneration. Int J Inflam (2013) 1.16
A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol (2009) 1.16
Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int (2004) 1.15
Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A (2006) 1.14
Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol (2006) 1.14
B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol (2010) 1.14
Peripheral CD4 T-cell depletion is not sufficient to prevent ischemic acute renal failure. Transplantation (2005) 1.12